Andrew David Berti Pharm.D.

Andrew David Berti Pharm.D.


Assistant Professor


Pharmacy Practice

Office Location

EACPHS, Room 4122




Andrew David Berti Pharm.D.

Degrees and Certifications

  • 2016 - Postdoctoral Fellowship, Antistaphylococcal Pharmacotherapy - University of Wisconsin-Madison
  • 2014 - Pharm.D. - University of Wisconsin-Madison, Madison WI
  • 2009 - Ph.D. Bacteriology - University of Wisconsin-Madison, Madison WI
  • 2003 - B.S. Microbiology - University of Rochester, Rochester NY

Positions and Employment

  • 2017-Present - Assistant Professor of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI
  • 2016-2017 - Infectious Diseases Research Scientist, University of Wisconsin-Madison, Madison, WI
  • 2014-2016 - Postdoctoral Research Fellow (Dr. Warren E. Rose), University of Wisconsin-Madison
  • 2010-2014 - Research Associate (Dr. Warren E. Rose), University of Wisconsin-Madison, Madison, WI
  • 2009-2010 - Quality Assurance Analyst, EPIC Systems Corporation, Verona, WI
  • 2003-2009 - Graduate Research Assistant (Dr. Michael G. Thomas), University of Wisconsin-Madison
  • 1999-2003 - Undergraduate Research Assistant (Dr. J. Scott Butler), University of Rochester, NY

Awards and Honors

  • 2019-2020 - Eugene Applebaum College of Pharmacy Faculty Research Award
  • 2018-2019 - Eugene Applebaum College of Pharmacy Faculty Research Award
  • 2018 - EACPHS Faculty Research Award (Individual)
  • 2016 - ASM Microbe Travel Award
  • 2014 - Zeeh Pharmaceutical Experiment Station Director’s Award in Science and Technology
  • 2014 - ICAAC Infectious Disease Fellow
  • 2013 - AACP Walmart Scholar
  • 2008 - Jerome Stefaniak Fellow, UW-Madison, Microbiology Doctoral Training Program
  • 2002 - DeKiewiet Fellow, University of Rochester

Professional Memberships

  • 2017 - European Society of Clinical Microbiology and Infectious Diseases
  • 2017 - Infectious Diseases Society of America
  • 2017 - American Association of Colleges of Pharmacy
  • 2012 - Society of Infectious Diseases Pharmacists
  • 2010 - Wisconsin Society of Pharmacy Students
  • 2010 - American Pharmacists Association
  • 2005 - American Society for Microbiology

Areas of Expertise

  • Antimicrobial Pharmacotherapy
  • Bacterial Metabolism
  • Secondary Metabolism/Metabolic Engineering
  • Molecular Biology
  • Recombinant Genetics
  • Enzymology
  • Pharmacokinetics/Pharmacodynamics
  • Mechanisms of Antimicrobial Resistance
  • Antimicrobial Tolerance

Primary Research Interest

The Berti Lab investigates how combining antibiotics in a deliberate and rational manner can improve outcomes for patients with challenging bacterial infections. We integrate pharmacokinetics, bacteriology, molecular biology, metabolism and recombinant genetics to examine when combination therapy is appropriate, why combination therapy can provide benefit and how best to administer antibiotic combinations.


  • Combination Antimicrobial Therapy
  • Mechanisms of Antimicrobial Resistance
  • Mechanisms of Antimicrobial Tolerance
  • Optimization of Pharmacological Interventions
  • Staphylococcus aureus

Recent Publications

  • Gortney JS, Fava JP, Berti AD, Stewart B. Comparison of student pharmacists’ performance on in-person vs. virtual OSCEs in a pre-APPE capstone course. Curr Pharm Teach Learn. 2022. In Press.
  • Berti AD, Kale-Pradhan PB, Giuliano CA et al. Clinical outcomes of zinc supplementation among COVID-19 patients. Curr Drug Saf. 2022.
  • Lew C, Pellitteri Hahn M, Scarlett C, Rottier A, Berti AD, Proctor RA, Bayer AS, Rose WE. Proteomic correlates of enhanced daptomycin activity following β-lactam pre-conditioning in daptomycin-resistant methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2022;66(3):e0201721.
  • Meredith EM, Berti AD. Commentary: Synergy between beta-lactams and lipo-glyco- and lipoglycopeptides is independent of the seesaw effect in methicillin-resistant Staphylococcus aureus. Front Mol Biosci. 2021;8:774021
  • Miller CR, Monk JM, Szubin R, Berti AD. Rapid resistance development to three antistaphylococcal therapies in antibiotic-tolerant Staphylococcus aureus bacteremia. PLoS One. 2021;16(10):e0258592.
  • Berti AD, Harven LT, Bingley V. Distinct effectiveness of oritavancin against tolerance-induced Staphylococcus aureus. Antibiotics. 2020;9(11):789.
  • Jenson RE, Baines SL, Howden BP, Mishra NN, Farah S, Lew C, Berti AD, Shukla SK, Bayer AS, Rose WE. Prolonged exposure to β-lactam antibiotics reestablishes susceptibility of daptomycin--nonsusceptible Staphylococcus aureus to daptomycin. Antimicrob Agents Chemother. 2020;64(9):e00890-20.
  • Berti AD, Rose WE, Nizet V, Sakoulas G. Antibiotics and innate immunity:a cooperative effort toward the successful treatment of infectious. Submitted to Clin Infect Dis, Feb 2020.
  • Miller CR, Dey S, Smolenski PD, Kulkarni PS, Baines SL, Berti AD. Suppression of daptomycin resistance development in Staphylococcus aureus is a class effect of beta lactams and is independent of daptomycin-beta lactam synergy. Submitted to Antimicrob Agents Chemother, Feb 2020.
  • Miller CR, Dey S, Smolenski PD, Kulkarni PS, Monk JM, Szubin R, Sakoulas G. Berti AD. Distinct subpopulations of intravalvular methicillin-resistant Staphylococcus aureus with variable susceptibility to daptomycin in tricuspid valve endocarditis. Antimicrob Agents Chemother. 2020;68(1):pii: AAC.01593-19.
  • Berti AD, Hirsch EB. Tolerance to antibiotics affects response. Science. 2020;367(6474):141-142.
  • Dey S, Gudipati S, Giuliano C, Zervos MJ, Monk JM, Szubin R, Jorgensen SCJ, Sakoulas G, Berti AD. Reduced production of bacterial membrane vesicles predicts mortality in ST45/USA600 methicillin-resistant Staphylococcus aureus bacteremia. Antibiotics (Basel). 2019;9(1):pii: E2.
  • Ritscher AM, Ranum N, Malak JD, Ahrabi-Fard S, Baird J, Berti AD, Curtis W, Holden M, Jones CD, Kind J, Kinsey W, Koepke R, Schauer SL, Stein E, VanOrman S, Ward BG, Zahner SJ, Hayney MS. Meningococcalserogroup B outbreak response at a large public university. J Amer Coll Health. 2019;67(3):191-196.
  • Berti AD, Shukla N, Rottier AD, McCrone JS, Turner HM, Monk IR, Baines SL, Howden BP, Proctor RA, Rose WE (in press). Daptomycin selects for genetic and phenotypic adaptations leading to antibiotic tolerance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2018;73(8):2030-2033.
  • Ritscher AM, Ranum N, Malak JD, Ahrabi-Fard S, Baird J, Berti AD, Curtis W, Holden M, Jones CD, Kind J, Kinsey W, Koepke R, Schauer SL, Stein E, VanOrman S, Ward BG, Zahner SJ, Hayney MS. Meningococcal serogroup B outbreak response at a large public university. J Am Coll Health. 2018;66(3):1-6
  • Fernandez-Llimos F, Berti AD, Yeung D et al. Scholarly publishing depends on peer reviewers. Pharm Pract. 2018;16(1):1236.
  • Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B. Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2018;62(2):e02100-17.
  • Berti AD, Schroeder JW, Rottier AD, McCrone JS, Wang J, Rose WE. Evolution of antibiotic tolerance during oxacillin, daptomycin and dalbavancin therapy results in breakthrough Staphylococcus aureus bacteremias. Open Forum Infect Dis. 2017;4(S1):S4.
  • Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G. Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia. Clin Infect Dis. 2017;64(10):1406-1412.
  • Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam-daptomycin synergy. Antimicrob Agents Chemother. 2015;60(1):451-458.
  • Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureusdetermined by adjunctive antibiotics. Antimicrob Agents Chemother. 2015;59(5):2799-2806.
  • Berti AD, Hutson PR, Schulz LT, Webb AP, Rose WE. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion. Am J Health Sys Pharm. 2015;72(5):390-395.
  • Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. β-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57(10):5005-5012.
  • Rose WE, Berti AD, Hatch JB, Maki DG. Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 2013;57(7):3450-3452.


Courses taught by Andrew David Berti Pharm.D.

Winter Term 2023 (current)

Fall Term 2022

Winter Term 2022